Justin Zelin
Stock Analyst at BTIG
(1.42)
# 3,321
Out of 4,854 analysts
37
Total ratings
23.53%
Success rate
-1.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Zelin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBRX ImmunityBio | Initiates: Buy | $6 | $3.15 | +90.48% | 1 | Jan 10, 2025 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $42 | $20.76 | +102.31% | 1 | Dec 13, 2024 | |
| CARM Carisma Therapeutics | Downgrades: Neutral | n/a | $0.19 | - | 2 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $55 → $62 | $21.72 | +185.45% | 2 | Jul 9, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Buy | $90 | $6.01 | +1,397.50% | 1 | Jul 8, 2024 | |
| TCRX TScan Therapeutics | Initiates: Buy | $12 | $1.81 | +564.82% | 1 | May 16, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Neutral | n/a | $24.28 | - | 2 | May 6, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $100 → $125 | $27.83 | +349.16% | 4 | Mar 26, 2024 | |
| VSTM Verastem | Assumes: Buy | $27 | $6.42 | +320.56% | 1 | Nov 21, 2023 | |
| MBIO Mustang Bio | Maintains: Buy | $1,000 → $800 | $1.24 | +64,416.13% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $91 | $37.38 | +143.48% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $0.76 | +1,220.48% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $0.98 | +1,536.66% | 1 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $37 | $10.25 | +260.98% | 2 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $35 | $11.45 | +205.68% | 1 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $90 | $35.00 | +157.14% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $6.73 | +360.62% | 1 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $16 | $74.63 | -79.23% | 1 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.18 | - | 3 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $10 | $1.86 | +437.09% | 3 | Nov 16, 2022 |
ImmunityBio
Jan 10, 2025
Initiates: Buy
Price Target: $6
Current: $3.15
Upside: +90.48%
Enliven Therapeutics
Dec 13, 2024
Initiates: Buy
Price Target: $42
Current: $20.76
Upside: +102.31%
Carisma Therapeutics
Dec 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.19
Upside: -
IDEAYA Biosciences
Jul 9, 2024
Maintains: Buy
Price Target: $55 → $62
Current: $21.72
Upside: +185.45%
Jasper Therapeutics
Jul 8, 2024
Initiates: Buy
Price Target: $90
Current: $6.01
Upside: +1,397.50%
TScan Therapeutics
May 16, 2024
Initiates: Buy
Price Target: $12
Current: $1.81
Upside: +564.82%
Lyra Therapeutics
May 6, 2024
Downgrades: Neutral
Price Target: n/a
Current: $24.28
Upside: -
Viking Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $100 → $125
Current: $27.83
Upside: +349.16%
Verastem
Nov 21, 2023
Assumes: Buy
Price Target: $27
Current: $6.42
Upside: +320.56%
Mustang Bio
Aug 15, 2023
Maintains: Buy
Price Target: $1,000 → $800
Current: $1.24
Upside: +64,416.13%
Aug 11, 2023
Maintains: Buy
Price Target: $85 → $91
Current: $37.38
Upside: +143.48%
Aug 10, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $0.76
Upside: +1,220.48%
Jul 25, 2023
Initiates: Buy
Price Target: $16
Current: $0.98
Upside: +1,536.66%
Jul 3, 2023
Maintains: Buy
Price Target: $30 → $37
Current: $10.25
Upside: +260.98%
Jun 26, 2023
Maintains: Buy
Price Target: $34 → $35
Current: $11.45
Upside: +205.68%
Jun 13, 2023
Maintains: Buy
Price Target: $85 → $90
Current: $35.00
Upside: +157.14%
May 17, 2023
Initiates: Buy
Price Target: $31
Current: $6.73
Upside: +360.62%
Mar 28, 2023
Maintains: Buy
Price Target: $10 → $16
Current: $74.63
Upside: -79.23%
Dec 6, 2022
Downgrades: Neutral
Price Target: n/a
Current: $2.18
Upside: -
Nov 16, 2022
Maintains: Buy
Price Target: $21 → $10
Current: $1.86
Upside: +437.09%